stockrow10x Genomics
TXG Healthcare Medical Devices
10x Genomics' revenue for fiscal 2025 (year ended December 2025) was $642.8 million, up 5.25% from fiscal 2024.
- Revenue
- +1.12%
- EPS
- +31.8%
- Free cash flow
- −4.61%
Quarter to September 2026, against a year earlier
Follow TXG
Alert me
10x Genomics (TXG) Shares outstanding
10x Genomics's shares outstanding at the end of fiscal 2025 was $124.7M, unchanged from fiscal 2024. At the end of the quarter to 30 September 2026 it was $130.8M. Over the past ten years it has ranged from $11.6M (fiscal 2017) to $124.7M (fiscal 2025) — the current reading is the highest in ten years. 10x Genomics ranks 26th of 147 Medical Devices companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $124.7M | 3.57% |
| FY2024 | $120.5M | 2.81% |
| FY2023 | $117.2M | 2.90% |
| FY2022 | $113.9M | 3.18% |
| FY2021 | $110.3M | 9.09% |
| FY2020 | $101.2M | 158.76% |
| FY2019 | $39.1M | 191.90% |
| FY2018 | $13.4M | 15.57% |
| FY2017 | $11.6M | — |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Sep 2026 | $130.8M | 0.63% |
| Jun 2026 | $130.0M | 1.32% |
| Mar 2026 | $128.3M | 2.84% |
| Dec 2025 | $124.7M | (0.60%) |
| 27 more quarters | Free account |
Against its own ten years
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| SNN Smith & Nephew SNATS, Inc. compare | $449.4M |
| BRKR Bruker Corporation compare | $152.5M |
| GMED Globus Medical, Inc. compare | $136.0M |
| TXG 10x Genomics | $130.0M |
| PODD Insulet Corporation compare | $69.5M |
| HAE Haemonetics Corporation compare | $46.5M |
| PEN Penumbra, Inc. compare | $39.6M |
| BIO.B Bio-Rad Laboratories, Inc. compare | $26.9M |
| BIO Bio-Rad Laboratories, Inc. compare | $26.9M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on TXG
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement